TY - JOUR
T1 - Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
AU - Faleck, David M.
AU - Winters, Adam
AU - Chablaney, Shreya
AU - Shashi, Preeti
AU - Meserve, Joseph
AU - Weiss, Aaron
AU - Aniwan, Satimai
AU - Koliani-Pace, Jenna L.
AU - Kochhar, Gursimran
AU - Boland, Brigid S.
AU - Singh, Siddharth
AU - Hirten, Robert
AU - Shmidt, Eugenia
AU - Kesar, Varun
AU - Lasch, Karen
AU - Luo, Michelle
AU - Bohm, Matthew
AU - Varma, Sashidhar
AU - Fischer, Monika
AU - Hudesman, David
AU - Chang, Shannon
AU - Lukin, Dana
AU - Sultan, Keith
AU - Swaminath, Arun
AU - Gupta, Nitin
AU - Siegel, Corey A.
AU - Shen, Bo
AU - Sandborn, William J.
AU - Kane, Sunanda
AU - Loftus, Edward V.
AU - Sands, Bruce E.
AU - Colombel, Jean Frederic
AU - Dulai, Parambir S.
AU - Ungaro, Ryan
N1 - Publisher Copyright:
© 2019 AGA Institute
PY - 2019/11
Y1 - 2019/11
N2 - Background & Aims: Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. Methods: We analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (>2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes. Results: Within 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02–2.49), CSFR (aHR, 3.39; 95% CI, 1.66–6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06–3.39). In contrast, disease duration was not a significant predictor of response among patients with UC. Conclusions: Patients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC.
AB - Background & Aims: Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. Methods: We analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (>2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes. Results: Within 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02–2.49), CSFR (aHR, 3.39; 95% CI, 1.66–6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06–3.39). In contrast, disease duration was not a significant predictor of response among patients with UC. Conclusions: Patients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC.
KW - Inflammatory Bowel Disease
KW - Integrin
KW - Monoclonal Antibody Therapy
KW - Time
UR - http://www.scopus.com/inward/record.url?scp=85064319966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064319966&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2018.12.040
DO - 10.1016/j.cgh.2018.12.040
M3 - Article
AN - SCOPUS:85064319966
SN - 1542-3565
VL - 17
SP - 2497-2505.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 12
ER -